Book Online or Call 1-855-SAUSALITO

Sign In  |  Register  |  About Sausalito  |  Contact Us

Sausalito, CA
September 01, 2020 1:41pm
7-Day Forecast | Traffic

  • Search Hotels in Sausalito

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biomea Fusion Inc (NQ: BMEA )

6.440 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biomea Fusion Inc

< Previous 1 2 3 4 5 6 7 8 Next >
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells with the aim to cure diabetes 
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Abstract “BMF-219: A Novel Therapeutic Agent to Reestablish Functional Beta Cells and Provide Long-term Glycemic Control" Selected as One of Six Oral Presentations at 21st World Congress Insulin Resistance, Diabetes & Cardiovascular Disease
BMF-219 is an investigational novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure diabetes 
From Biomea Fusion, Inc.
Via GlobeNewswire
14 Analysts Have This to Say About Biomea Fusion
Via Benzinga
Biomea Fusion to Present New Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes at the World Congress Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
BMF-219 is an investigational novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 2 diabetes 
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Announces Two Poster Presentations at Upcoming ASH Annual Meeting 2023
From Biomea Fusion, Inc.
Via GlobeNewswire
Why Biomea Fusion Stock Is Falling Today?
Biomea Fusion Inc (NASDAQ: BMEA) released preliminary topline data from its ongoing Phase 1 COVALENT-101 trial, showcasing initial responses in relapsed/refractory AML patients with  
Via Benzinga
What 18 Analyst Ratings Have To Say About Biomea Fusion
Via Benzinga
Analyst Ratings for Biomea Fusion
Via Benzinga
Recap: Biomea Fusion Q1 Earnings
Via Benzinga
Biomea Fusion Reports Third Quarter 2023 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Announces First Patient Dosed with Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia in Phase I Clinical Trial (COVALENT-103)
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Announces FDA Clearance of Investigational New Drug (IND) Application for BMF-219 in Type 1 Diabetes
BMF-219 is a novel covalent menin inhibitor designed to regenerate insulin-producing beta cells with the aim to cure type 1 diabetes 
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Announces FDA and Health Canada Clearance of the Expansion Cohorts of the Ongoing COVALENT-111 Phase II Study
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Announces Appointment of Juan Pablo Frías, M.D. as Chief Medical Officer
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion Reports Second Quarter 2023 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For July 27, 2023
Via Benzinga
BMF-219 Induces Complete Responses in Target Acute Myeloid Leukemia (AML) Patient Population
From Biomea Fusion, Inc.
Via GlobeNewswire
Why Ryanair Holdings Shares Are Trading Lower By 8%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Tupperware Brands Corporation (NYSE: TUP) shares jumped 59% to $1.43 on above-average volume amid retail investor interest. 
Via Benzinga
Are (More) Big Gains Ahead for This Small Cap Biotech Stock?
With Biomea Fusion's share price nearly halved recently, oversold conditions seem to be setting in. This could be an opportunity for small cap growth investors. 
Via MarketBeat
Topics Initial Public Offering
Exposures Securities Market
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the Firm
From The Schall Law Firm
Via Business Wire
Dow Surges Over 50 Points; Avalo Therapeutics Shares Plummet
U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining more than 50 points on Monday. The Dow traded up 0.18% to 33,788.05 while the NASDAQ fell 0.61% to 13,410.63. The S&P 500,... 
Via Benzinga
Crude Oil Rises; Carnival Shares Drop After Q2 Results
U.S. stocks traded lower midway through trading, with the Nasdaq dropping around 80 points on Monday. The Dow traded down 0.02% to 33,719.54 while the NASDAQ fell 0.53% to 13,420.67. The S&P 500, also... 
Via Benzinga
Biomea Fusion Stock Is Trading Higher Today - Here's Why
Biomea Fusion Inc (NASDAQ: BMEA) announced the presentation of new clinical data from the first two cohorts from the Phase 2 portion of its ongoing Phase 1/2 clinical study (COVALENT-111) of BMF-219... 
Via Benzinga
Why Carnival Shares Are Trading Lower By 9%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Benitec Biopharma Inc. (NASDAQ: BNTC) climbed 104% to $0.4050 after the company announced it received FDA clearance of the IND for BB-301 for the treatment of Oculopharyngeal Muscular... 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start off the week right with a breakdown of the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
Biomea Fusion Presents Positive Clinical Data from the Initial Cohorts of the Ongoing Phase II Study (COVALENT-111) of BMF-219 in Patients with Type 2 Diabetes Mellitus at the American Diabetes Association (ADA) 83rd Scientific Sessions; 100 mg Cohort 3
From Biomea Fusion, Inc.
Via GlobeNewswire
Biomea Fusion to Present Late Breaking Data from Ongoing Phase II Trial, COVALENT-111, Evaluating BMF-219 in Patients with Type 2 Diabetes at ADA 2023
From Biomea Fusion, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For May 12, 2023
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Photos copyright by Jay Graham Photographer
Copyright © 2010-2020 Sausalito.com & California Media Partners, LLC. All rights reserved.